
    
      A single center, open label, Phase IIa, Idea, Development, Exploration, Assessment, Long-term
      follow-up (IDEAL) prospective development study. The study will treat approximately 20 men
      who meet the eligibility criteria, and give written informed consent. Safety and Tolerability
      will be assessed post-treatment at 2 days (phone call), 2 weeks, 6 weeks, 12 weeks, 24 weeks
      and 26 weeks. Potential Efficacy will be assessed by biopsy at 24 weeks and imaging (MRI) at
      2 weeks, 12 weeks and 24 weeks and PSA outcomes at 12 and 24 weeks.
    
  